NaDeNo is a close-to-clinic biotech enabling nanoparticle therapeutics for hard-to-deliver drugs
Our team combines decade-long experience with the platform technology with deep industry expertise across clinical drug development.
By leveraging solid partners, NaDeNo is able to advance our lead candidate through clinical development while broadening the platform with attractive pipeline projects.
Team
NaDeNo’s team has deep experience developing and utilizing our drug delivery platform technology, combined with solid experience across clinical development of novel therapeutics.
Jens Bjørheim
Chief Medical Officer
Tore Kvam
Chief Financial Officer
Gudrun Trøite
Head of Operations
Sofie Snipstad
Senior Scientist
Erik Møller Steen
Project & Business Development Manager
Board of Directors
The NaDeNo Board of Directors includes highly experienced senior executives with broad and deep experience across the life science industry and clinical drug development.
Ole Dahlberg
Chair of the Board
Jostein Bjøndal
Board Member
Cristianne Rijcken
Board Member
Jonas Hallén
Board Member
Martin Welschof
Board Member
Scientific Advisors
NaDeNo is supported by scientific advisors across clinical development, research & development, and business strategy.
Ingrid Boere
Clinical advisor
Wim P. Ceelen
Clinical Advisor
Ron Mathijssen
Clinical Advisor
Andreas Åslund
Tech Development
Geir Klinkenberg
Tech Development
Kjersti Flatmark
Clinical Research
Ruth Schmid
Strategic Advisor
Arthur Tipton
Strategic Advisor
Anton Mat
Business Development
Annbjørg Falck
Co-founder & Chief Executive Officer
Yrr Mørch
Co-founder & Chief Technology Officer
Stijn Koolen
Clinical Advisor
Partners
NaDeNo collaborates with leading institutions across healthcare and research ecosystems.
